Teva Secures FDA Acceptance for Once-Monthly Schizophrenia Treatment
Event summary
- Teva and Medincell received FDA acceptance for a New Drug Application (NDA) for olanzapine extended-release injectable suspension (TEV-'749) for schizophrenia treatment.
- TEV-'749 offers a once-monthly subcutaneous formulation, potentially eliminating the need for a 3-hour post-injection monitoring period required by current long-acting olanzapine treatments.
- The NDA is based on Phase 3 SOLARIS trial data, demonstrating efficacy and safety consistent with existing olanzapine formulations.
- TEV-'749 utilizes Medincell’s SteadyTeq™ technology for controlled drug release.
The big picture
The acceptance of TEV-'749 represents a potential shift in schizophrenia treatment paradigms, addressing a significant unmet need for improved adherence and reduced healthcare burden. Current treatments often require frequent administration and monitoring, contributing to relapse rates and high costs. Medincell’s SteadyTeq™ technology, licensed to Teva, could become a valuable platform for developing other long-acting injectable therapies, potentially expanding Teva’s LAI franchise and bolstering its 'Pivot to Growth' strategy.
What we're watching
- Regulatory Review
- The FDA’s review timeline and potential requests for additional data will be critical in determining the launch date and commercial viability of TEV-'749.
- Market Adoption
- The success of TEV-'749 will depend on physician and patient acceptance of a once-monthly injectable, particularly given existing adherence challenges and patient preferences.
- Competitive Landscape
- How Teva positions TEV-'749 against existing long-acting antipsychotics and potential future entrants will influence its market share and pricing power.
Related topics